BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1
- DOI
- 10.1016/j.htct.2023.09.842
- Published
- 2023-10
- Container
- Hematology, Transfusion and Cell Therapy
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.htct.2023.09.842,
title = {BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1},
author = {MC Ozelo and J Mahlangu and B Madan and J Mason and F Peyvandi and AV Drygalski and G Yamaguti-Hayakawa and TM Robinson and SW Pipe and TT Gener-Eigh},
year = {2023},
journal = {Hematology, Transfusion and Cell Therapy},
doi = {10.1016/j.htct.2023.09.842},
url = {https://doi.org/10.1016/j.htct.2023.09.842}
}RIS
TY - JOUR TI - BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1 AU - MC Ozelo AU - J Mahlangu AU - B Madan AU - J Mason AU - F Peyvandi AU - AV Drygalski AU - G Yamaguti-Hayakawa AU - TM Robinson AU - SW Pipe AU - TT Gener-Eigh PY - 2023 JO - Hematology, Transfusion and Cell Therapy DO - 10.1016/j.htct.2023.09.842 UR - https://doi.org/10.1016/j.htct.2023.09.842 ER -
APA
Ozelo, M., Mahlangu, J., Madan, B., Mason, J., Peyvandi, F., Drygalski, A., Yamaguti-Hayakawa, G., Robinson, T., Pipe, S., & Gener-Eigh, T. (2023). BLEEDING, FVIII ACTIVITY, AND SAFETY 3 YEARS AFTER GENE TRANSFER WITH VALOCTOCOGENE ROXAPARVOVEC: RESULTS FROM GENER8-1. Hematology, Transfusion and Cell Therapy. https://doi.org/10.1016/j.htct.2023.09.842
Source records
- crossref · retrieved 2026-09-26T10:01:04.711Z